This Diagnostic Chain Stock Rises 43% in 1 Year: What Is Powering the Re-Rating?

This diagnostic chain stock has risen approximately 43% in one year, with no bonus issue, stock split or one-off gain flattering the figure. It closed at Rs 1,049.90 on 17 September 2025 and traded at Rs 1,501.80 on 17 September 2026, a close-to-close gain of 43.04%.

The company is Vijaya Diagnostic Centre Ltd (NSE: VIJAYA), a Hyderabad-headquartered pathology and radiology network running 166 centres. It was among the stronger names on a screen of NSE small-cap stocks ranked by 1-year return, dated 17 September 2026. What sets this diagnostic chain stock apart from a typical small-cap runner is that the move tracks five straight quarters of margin expansion, not a promised order book.

Click Here – Get Free Investment Predictions

How Much Has This Diagnostic Chain Stock Returned Across Time Frames?

The one-year return is 43%, the six-month return roughly 59%, and the one-month return slightly negative. The entire gain in this diagnostic chain stock came in a single burst between April and August 2026.

Through the second half of 2025 this diagnostic chain stock actually fell, bottoming at Rs 848 in the week ended 30 March 2026. From there it has climbed roughly 77%. A buyer at the September 2025 level waited seven months to break even.

Period	Start Price (Rs)	Price on 17 Sep 2026 (Rs)	Price Return
1 Month (17 Aug 2026)	1,506.60	1,501.80	Down 0.32%
6 Months (17 Mar 2026)	941.90	1,501.80	Up 59.44%
1 Year (17 Sep 2025)	1,049.90	1,501.80	Up 43.04%
3 Years (15 Sep 2023)	492.40	1,501.80	Up 204.99%
5 Years (17 Sep 2021)	627.00	1,501.80	Up 139.52%

Returns are simple price changes, not annualised. The three-year figure beats the five-year one because this diagnostic chain stock listed in September 2021 at a rich valuation and then fell through 2022. The 52-week range is Rs 848 to Rs 1,578.

Why Did This Diagnostic Chain Stock Rise 43% in One Year?

Four dated events did the work: FY26 results on 7 May 2026, June quarter results on 6 August 2026, a target upgrade on 10 August 2026 and an acquisition on 11 September 2026. Together they re-rated this diagnostic chain stock from a PE in the fifties to near 80.

1. FY26 Results on 7 May 2026: Revenue Crossed Rs 800 Crore

March-quarter revenue was Rs 219.4 crore, up 26.6%, with EBITDA of Rs 95.5 crore at a 43.5% margin and profit after tax up 37.5% to Rs 47.9 crore. Full-year revenue for this diagnostic chain stock reached Rs 814.2 crore and net profit Rs 173.0 crore.

Tests rose 18.5% to 4.49 million and footfalls 15.8% to 1.21 million, so growth was volume-led. The board recommended a dividend of Rs 2 per share on a face value of Re 1. The Vijaya Diagnostic share price jumped from about Rs 1,139 to Rs 1,299 the following week.

2. June Quarter Results on 6 August 2026: Margin at 42.7%

Revenue for the June 2026 quarter was Rs 231.0 crore, up 22.8%, with EBITDA up 34.0% to Rs 98.5 crore. The EBITDA margin expanded 356 basis points to 42.7% and profit after tax rose 37.6% to Rs 53.1 crore, a net margin of 23.0%.

Footfalls grew 12.7% to 1.24 million and test volumes 16.5% to 4.59 million, with revenue per test at Rs 503. Roughly 92% of revenue came from direct-to-consumer channels, which is why this diagnostic chain stock earns better margins than institution-led lab networks.

3. A Target Upgrade on 10 August 2026

Four days later a domestic brokerage lifted its Vijaya Diagnostic share price target to Rs 1,600 with a buy rating. The share rose from Rs 1,428 to Rs 1,510 on 12 August 2026 on volume near 1.4 million shares, roughly ten times normal turnover in this diagnostic chain stock.

4. New Cities and the Guwahati Acquisition on 11 September 2026

A Gachibowli hub opened in April 2026 with a 160-slice cardiac CT and a Bengaluru hub with advanced imaging in July 2026. Four hubs were commissioned in the December 2025 quarter: Phoolbagan and Diamond Harbour in West Bengal, plus Khammam and Nandyal.

On 11 September 2026 the company agreed to buy the diagnostic business of Arya Wellness Centre in Guwahati for Rs 46.20 crore on a slump-sale basis, closing within 90 days. That unit earned Rs 26.95 crore in FY26. Management says its earlier West Bengal centres broke even within three quarters against a one-year plan, the detail buyers of this diagnostic chain stock watch closely.

Check the Univest Screener for Live Fundamentals of High-Return Stocks

What Do the Financials Behind This Diagnostic Chain Stock Look Like?

Revenue and margins have both risen for five consecutive quarters at this diagnostic chain stock. Total income moved from Rs 195.10 crore in the June 2025 quarter to Rs 239.51 crore in June 2026, while the operating margin widened from 42.85% to 46.35%.

Quarter	Total Income (Rs Cr)	EBITDA (Rs Cr)	Net Profit (Rs Cr)	Operating Margin	Net Margin
Jun 2025	195.10	80.58	38.59	42.85%	20.52%
Sep 2025	207.81	88.08	43.28	43.70%	21.47%
Dec 2025	210.31	91.16	43.18	44.42%	21.04%
Mar 2026	221.78	97.92	47.93	44.63%	21.85%
Jun 2026	239.51	107.07	53.10	46.35%	22.99%

Those margins are computed on total income, so they sit above the 42.7% the company reports on net revenue. Rising margins on rising volumes are what the market pays for in a diagnostic chain stock.

Annually, total income grew from Rs 568.62 crore in FY24 to Rs 699.71 crore in FY25 and Rs 835.0 crore in FY26, with net profit rising from Rs 119.64 crore to Rs 172.98 crore. Operating cash flow of Rs 270.59 crore in FY26 covered capital expenditure of Rs 182.72 crore, so the build-out is self-funded.

Total equity was Rs 957.15 crore in FY26 with debt to equity of 0.42, now around 0.44. Return on equity is 18.07%, book value per share Rs 92.93 and trailing EPS Rs 18.20 for this diagnostic chain stock.

Who Owns This Diagnostic Chain Stock?

Domestic institutions have been buying this diagnostic chain stock while foreign institutions sell. DII holding climbed from 24.07% in June 2025 to 31.61% in June 2026, while FII holding fell from 19.56% to 11.66% across the same five quarters.

Shareholder	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Promoters	52.63%	52.60%	52.60%	52.51%	52.51%
FII	19.56%	18.27%	15.10%	13.38%	11.66%
DII	24.07%	25.34%	28.59%	29.93%	31.61%
Public	3.74%	3.79%	3.71%	4.18%	4.23%

Promoter holding eased only from 52.63% to 52.51% over the year and no pledge is disclosed. The largest domestic holders in June 2026 were a small-cap fund at 6.59% and a multi-cap fund at 5.64%. A 4.23% public float leaves this diagnostic chain stock thinly traded.

Is This Diagnostic Chain Stock Expensive After a 43% Rise?

Yes, on trailing numbers it is. The Vijaya Diagnostic share price of Rs 1,501.80 implies a PE of approximately 79 against an industry PE near 67, and a price to book of about 15.5. Market capitalisation is roughly Rs 14,800 crore.

The counter-argument is that earnings are compounding faster than the multiple. Trailing profit growth is close to 30% and margins are still widening, so a PE of 79 falls sharply on forward earnings if the June quarter run rate holds. A dividend yield of 0.14% means the case for this diagnostic chain stock rests wholly on growth.

Key Risks Before Buying This Diagnostic Chain Stock

Geographic concentration: the core southern market still contributes approximately 67% of revenue. A local pricing war or a regulatory change in Telangana would hit this diagnostic chain stock harder than a spread-out peer.

Liquidity and volatility: with a 4.23% public float, a single institutional order moves the price. On 15 and 16 September 2026 the Vijaya Diagnostic share price fell from Rs 1,502 to an intraday low of Rs 1,380, then bounced roughly 4.4% on 17 September. Exiting this diagnostic chain stock during a sell-off can be costly.

Valuation risk: a PE near 79 and a price to book above 15 leave no cushion. If quarterly revenue growth slips from the low twenties to the low teens, the multiple compresses fast. That is what happened between September 2025 and March 2026, when this diagnostic chain stock fell roughly 19% while earnings grew.

Expansion and integration risk: Kolkata, Bengaluru and Guwahati sit outside the core market. New hubs carry rent, equipment and staff costs before revenue ramps, and the Rs 46.20 crore Guwahati purchase has not closed. A slow ramp hits the margin line this diagnostic chain stock is rewarded for.

Competition and pricing: national chains, hospital-linked labs and online aggregators discount routine panels aggressively. Revenue per test of Rs 503 is the number to track each quarter, since volume bought through discounting would undo this diagnostic chain stock's margin story.

Foreign selling: FII holding has fallen for five straight quarters, from 19.56% to 11.66%. Domestic funds have absorbed that supply, but if inflows slow while foreign selling continues, this diagnostic chain stock could drift regardless of business performance.

Download the Univest iOS App or Univest Android App to track the Vijaya Diagnostic share price live

Vijaya Diagnostic Share: Analyst View

Analyst coverage is positive, but the share has caught up with it. A consensus of ten analysts tracked in the three months to mid-September 2026 carries eight buy ratings, one hold and no sell ratings on the Vijaya Diagnostic share.

The debate is whether the EBITDA margin holds in the 42% to 43% band, whether tests per footfall stay above 3.7, and how fast new-city hubs break even. Those three variables decide where this diagnostic chain stock trades over the next two years.

Vijaya Diagnostic Share Price Target

The consensus Vijaya Diagnostic share price target is approximately Rs 1,530, with a high of Rs 1,700 and a low of Rs 1,300. Against Rs 1,501.80 on 17 September 2026 that implies upside under 2%, so the average analyst sees this diagnostic chain stock as close to fairly valued.

The most recent revision was a domestic brokerage lifting its target to Rs 1,600 on 10 August 2026, while a June 2026 consensus of Rs 1,363 has already been passed. A Vijaya Diagnostic share price target is an estimate built on volume and margin assumptions, not a promise, and the 52-week high of Rs 1,578 is the nearer reference point.

Other Stocks to Track From the Same Return Screen

Beyond this diagnostic chain stock, a screen of NSE small-cap stocks ranked by 1-year return also includes related names such as Strides Pharma with a 1-year return of 35.71%, SPARC at 33.17% and South Indian Bank at 56.49%.

Among the names covered from that screen, MTAR Technologies returned 396.53% over one year. Readers can compare this diagnostic chain stock with the Nifty 50 benchmark and track each of these names on Univest before making any decision.

Conclusion

This diagnostic chain stock earned its 43% one-year gain with reported numbers rather than announcements. Margins widened five quarters running, June quarter profit grew 37.6%, capital expenditure came out of operating cash flow, and promoters stayed at 52.51% while domestic funds raised their stake to 31.61%.

The counterweight is price. At a PE near 79 the Vijaya Diagnostic share already discounts several years of growth, and a 4.23% float makes it move sharply both ways. For anyone weighing this diagnostic chain stock, quarterly tracking of footfalls, revenue per test and the Guwahati integration matters more than any target price.

Frequently Asked Questions

Which diagnostic chain stock rose 43% in one year?

Ans. Vijaya Diagnostic Centre Ltd (NSE: VIJAYA) is the diagnostic chain stock that gained 43.04% between 17 September 2025 and 17 September 2026, from Rs 1,049.90 to Rs 1,501.80. No bonus issue or stock split occurred in the period.

What is the current Vijaya Diagnostic share price?

Ans. The Vijaya Diagnostic share price was Rs 1,501.80 on 17 September 2026, up approximately 4.4% from the previous close of Rs 1,438.30. The 52-week range is Rs 848 to Rs 1,578.

Why did this diagnostic chain stock rise in 2026?

Ans. Four dated triggers drove it: FY26 results on 7 May 2026 showing revenue of Rs 814.2 crore, June quarter results on 6 August 2026 with a 42.7% EBITDA margin, a brokerage target upgrade on 10 August 2026, and the Guwahati acquisition on 11 September 2026.

What were the Q1 FY27 results of Vijaya Diagnostic?

Ans. Revenue for the June 2026 quarter was Rs 231.0 crore, up 22.8%, and profit after tax was Rs 53.1 crore, up 37.6%. EBITDA rose 34.0% to Rs 98.5 crore with the margin up 356 basis points to 42.7%, and the network stood at 166 centres.

What is the Vijaya Diagnostic share price target?

Ans. The consensus target is approximately Rs 1,530, with a high of Rs 1,700 and a low of Rs 1,300 across ten analysts. A domestic brokerage set Rs 1,600 with a buy rating on 10 August 2026, and targets are estimates, not assurances.

Is this diagnostic chain stock overvalued at a PE of 79?

Ans. It trades at a clear premium, with a PE of approximately 79 against an industry PE of around 67. That holds only if profit keeps growing near 30% and the EBITDA margin stays in the 42% to 43% band, so any slowdown would compress the multiple.

Have promoters or institutions sold Vijaya Diagnostic shares?

Ans. Promoter holding is unchanged in substance at 52.51% in June 2026 against 52.63% a year earlier, with no disclosed pledge. Foreign institutional holding fell from 19.56% to 11.66% over five quarters while domestic holding rose from 24.07% to 31.61%.

What are the biggest risks in this diagnostic chain stock?

Ans. The main risks are geographic concentration, with approximately 67% of revenue from the core southern market, and a stretched valuation. A public float of 4.23% also makes this diagnostic chain stock volatile, as the drop from Rs 1,502 to Rs 1,380 on 15 and 16 September 2026 showed.